Trial of Adcetris in CD30+ Malignant Mesothelioma

Primary Outcome Measures

• Disease Control Rate (DCR) in Pre-Treated Participants with Unresectable Malignant Pleural Mesothelioma (MPM) Treated with Brentuximab Vedotin [ Time Frame: 4 months ]
  Disease control rate (DCR) defined as proportion of patients who had complete response, partial response or stable disease by RESIST 4.1.

Secondary Outcome Measures

• Time to Progression in Pre-Treated Participants with Unresectable Malignant Pleural Mesothelioma (MPM) Treated with Brentuximab Vedotin [ Time Frame: 6 weeks ]
  Time to progression assessed by RESIST 4.1. Time to progression estimated using the method of Kaplan and Meier.

Detailed Description

Study Drug Administration:
There are 21 days (about 3 weeks) in each study cycle. If participant is found to be eligible to take part in this study, participant will receive brentuximab vedotin by vein over 30 minutes on Day 1 of every cycle.

Length of Study:

Participant may continue taking the study drug for as long as the doctor thinks it is in participant’s best interest. Participant will no longer be able to take the study drug if the disease gets worse, if intolerable side effects occur, or if participant is unable to follow study directions.

Participation on this study will be over after participant has completed follow-up (described below).

Study Visits:

On Day 1 of every cycle:

Follow-Up:

The study doctor or study team will follow up with participant about 30 days after participant’s last dose of brentuximab vedotin by either reviewing participant’s medical record or calling participant to learn if participant has had any side effects.

Participant will continue to have these follow-ups at 3 months, 6 months, and then every 6 months after that while participant is on study.

This is an investigational study. Brentuximab vedotin is FDA approved and commercially available for the treatment of Hodgkin lymphoma and anaplastic large cell lymphoma. It is considered investigational to use brentuximab vedotin in patients with mesothelioma. The study doctor can explain how the study drug is designed to work.

Up to 50 participants will be enrolled in this study. All will take part at MD Anderson.

Eligibility

Inclusion Criteria

Voluntary written informed consent before performance of any study-related procedure not part of normal medical care, with the understanding that consent may be withdrawn by the subject at any time without prejudice to future medical care.

Female subject is either: a. post-menopausal for at least one year before the screening visit; or b. surgically sterilized; or c. willing to use an acceptable method of birth control (ie, a hormonal contraceptive, intra-uterine device, diaphragm with spermicide, condom with spermicide, or abstinence) for the duration of the study and at least 6 months after the last dose of brentuximab vedotin.

Male subject, even if surgically sterilized (ie, status postvasectomy), agrees to use an acceptable barrier method for contraception (condom with a spermicidal agent), or completely abstain from heterosexual intercourse during the entire study treatment period through 6 months after the last dose of brentuximab vedotin.

Absolute neutrophil count (ANC) > 1500/mm³, platelets > 100,000/mm³, Hgb > 8.5 g/dL.

Total bilirubin Adequate renal function as defined by: Calculated creatinine clearance must be >/= 30 mL/minute

Eastern Cooperative Oncology Group (ECOG) performance status 0-2

Pathologic diagnosis of malignant mesothelioma (any primary site is acceptable, any histology is acceptable)

Have unresectable malignant mesothelioma (any histology)

Positive CD30+ immunohistochemical expression

Any line of prior therapy – patients may be chemo-naïve or chemo-refractory (any line)

Patients must have measurable disease by modified RECIST or RECIST. Examinations for assessment of measurable disease must have been completed within 28 days prior to registration.

Patient must be >/= 18 years of age

Exclusion Criteria

Radiation therapy to more than 25% of the bone marrow. Whole pelvic radiation is considered to be over 25%.

Prior allogeneic bone marrow or organ transplantation

Female subject who is pregnant or breast-feeding. Confirmation that the subject is not pregnant must be established by a negative serum Beta-human chorionic gonadotropin (B-hCG) pregnancy test result obtained during screening. Pregnancy testing is not required for post-menopausal or surgically sterilized women.

Patient has received other investigational drugs with 14 days before enrollment

Serious medical or psychiatric illness likely to interfere with participation in this clinical study.

No prior history of malignancy within 2 years, unless cured of a skin cancer or a stage I-III solid tumor. No prior hematologic malignancy within 3 years.

Known hypersensitivity to brentuximab vedotin components

Persons who are incarcerated at time of enrollment (e.g., prisoners) or likely to become incarcerated during the study